Tradestie Institutional Equity Comparison Engine
OCS vs CRMD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRMD Overall Edge
CRMD Captures Institutional Edge (3โ1 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CorMedix Inc. (CRMD) driven by superior Valuation, Growth & Margin, Momentum & Technical while OCS counters with relative strength in Options & Structure. Fundamentally, OCS trades at N/M Forward P/E with -9558.9% operating margin (-97.1% YoY revenue) versus CRMD at 49.0x Forward P/E and 41.0% operating margin (-47.7% YoY). In options structure, OCS sits in BREAKDOWN (3rd %ile IV; Dealer Gamma Walls on Pro) against CRMD sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CRMD
OCS N/M vs CRMD 49.0x Fwd P/E
Growth & Margin Winner
CRMD
Op Margin -9558.9% vs 41.0% ยท YoY -97.1% vs -47.7%
Momentum & Technical Winner
CRMD
1Y -60.8% vs -56.2% ยท 52W Pos 3% vs 3%
Options & Structure Winner
OCS
BREAKDOWN (3rd %ile IV) vs BREAKDOWN (25th %ile IV)
OCS
NASDAQ
Oculis Holding AG Ordinary shares
Pharmaceutical Preparations
$7.55
-1.11% 1D
Market Cap
$417.9M
1M Return
+3.64%
1Y Return
-60.83%
Forward P/E
N/M
Unified AI Score
39.9 / 100
SELL
Tech 35.0
Fund 48.0
Flow 66.0
Mom 50.0
CRMD
NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.92
+5.47% 1D
Market Cap
$384.7M
1M Return
-32.3%
1Y Return
-56.16%
Forward P/E
49.0x
Unified AI Score
53.2 / 100
HOLD
Tech 60.0
Fund 60.0
Flow 69.0
Mom 55.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
OCS -60.83%
CRMD -56.16%
Spread: +4.67 pp (CRMD Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
OCS TTM Op. Margin: -9558.9%
CRMD TTM Op. Margin: 41.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OCS vs CRMD. Trailing 12-month operating profitability (OCS -9558.9% vs CRMD 41.0%) and valuation multiples (OCS N/M vs CRMD 49.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | OCS | CRMD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $417.9M | $384.7M | Larger Scale | OCS |
| Trailing P/E Ratio Valuation | N/M | 2.4x | Lower Multiple | CRMD |
| Forward P/E Ratio Valuation | N/M | 49.0x | Lower Multiple | CRMD |
| Revenue Growth (YoY) Growth | -97.1% | -47.7% | Higher Growth | CRMD |
| Operating Margin (TTM) Profitability | -9558.9% | 41.0% | Higher Margin | CRMD |
| Net Profit Margin Profitability | 0.0% | 15.5% | Higher Margin | CRMD |
| Return on Equity (ROE) Capital Efficiency | -47.5% | 15.3% | Higher ROE | CRMD |
| 52-Week Range Position Momentum | 3% ($7โ$34) | 3% ($5โ$13) | Stronger Trend | Tie |
| Beta / 30D Volatility Risk Regime | 1.14ฮฒ ยท 60% Vol | 1.20ฮฒ ยท 107% Vol | Lower Realized Risk | OCS |
| Unified Institutional Score Composite Signal | 39.9 / 100 (SELL) | 53.2 / 100 (HOLD) | Higher Composite | CRMD |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full OCS vs CRMD Buy Guide
OCS
BREAKDOWN
131d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
3rd %ile
IV Regime
Compressed (<25th %ile)
CRMD
BREAKDOWN
109d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
25th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither OCS nor CRMD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.